Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jeffrey A. Carrell
Observed names:
J Carrell,
J. Carrell,
Jeffrey Carrell
Institutions:
Frederick National Laboratory for Cancer Research,
National Cancer Institute,
Center for Cancer Research
Observed institutions:
Human Genome Sciences (United States),
National Institutes of Health,
Frederick National Laboratory for Cancer Research,
National Cancer Institute,
Center for Cancer Research
ORCID:
0000-0001-7484-4407
Observed ORCID:
0000-0001-7484-4407
OpenAlex ID:
A5007893848
BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
1999
·
Paul A. Moore
, Ornella Belvedere
, et al.
·
Science
·
1,217
TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator
2002
·
Thi-Sau Migone
, Jun Zhang
, et al.
·
Immunity
·
692
PDF
Synthesis and release of B-lymphocyte stimulator from myeloid cells
2001
·
Bernardetta Nardelli
, Ornella Belvedere
, et al.
·
Blood
·
625
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
2005
·
L Pukac
, P Kanakaraj
, et al.
·
British Journal of Cancer
·
324
PDF
A Novel Cytokine Receptor-Ligand Pair
2000
·
Yanggu Shi
, Stephen J. Ullrich
, et al.
·
Journal of Biological Chemistry
·
257
AlbugraninTM, a Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Genetically Fused to Recombinant Human Albumin Induces Prolonged Myelopoietic Effects in Mice and Monkeys
2002
·
Wendy Halpern
, Todd A. Riccobene
, et al.
·
Pharmaceutical Research
·
91
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
2009
·
Troy A. Luster
, Jeffrey A. Carrell
, et al.
·
Molecular Cancer Therapeutics
·
71
Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BLyS) in Mice
2001
·
Tom J. Parry
, Todd A. Riccobene
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
51
CD19-positive antibody-secreting cells provide immune memory
2018
·
C. J. Groves
, J. Carrell
, et al.
·
Blood Advances
·
28
Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
2012
·
Troy A. Luster
, Ipsita Mukherjee
, et al.
·
PLoS ONE
·
13
PDF
OMIP‐043: Identification of human antibody secreting cell subsets
2017
·
Jeffrey Carrell
, Christopher J. Groves
·
Cytometry Part A
·
12
PDF
Isolation of single cells from individual mouse ovaries for flow cytometry and functional analysis
2023
·
Enitome E. Bafor
, Toni Martin
, et al.
·
STAR Protocols
·
9
Tag-on-Demand: exploiting amber codon suppression technology for the enrichment of high-expressing membrane protein cell lines
2018
·
Zachary T Britton
, Timothy B London
, et al.
·
Protein Engineering Design and Selection
·
5
The KIR2DL1 intermediate upstream element participates in gene activation
2023
·
Paul W. Wright
, Hongchuan Li
, et al.
·
Immunogenetics
·
4
PDF
Supplementary Fig. S1 from Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
2023
·
Troy A. Luster
, Jeffrey A. Carrell
, et al.
PDF
Data from Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
2023
·
Troy A. Luster
, Jeffrey A. Carrell
, et al.
Data from Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
2023
·
Troy A. Luster
, Jeffrey A. Carrell
, et al.
Abstract 3861: Fusion toxin BLyS-gelonin inhibits growth of B-NHL cell lines in vitro and in vivo
2012
·
Troy A. Luster
, Ipsita Mukherjee
, et al.
·
Cancer Research
Show more works
View as search
Works count:
18
Citation count:
3,399
H-index:
11
I10-index:
11
Year
Topic
Type